ORSERDUHCP.COM: Keyword Density Checker

Total words: 2789 | 2-word phrases: 721 | 3-word phrases: 809 | 4-word phrases: 847

PAGE INFO

Title	Try to keep the title under 60 characters (60 characters) Oral ER+/HER2- ESR1m mBC Treatment \| ORSERDU® (elacestrant)
Description	Try to keep the meta description between 50 - 160 characters (158 characters) Learn about Orserdu®, the first and only approved select estrogen receptor degrader (SERD) oral therapy, for ER+/HER2- ESR1-mutated metastatic breast cancer.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (1 characters) +

#	Keyword	Frequency	Density
1	of patients who	6	0.74%
2	patients who received	6	0.74%
3	and for 1	6	0.74%
4	orserdu and for	5	0.62%
5	in patients with	5	0.62%
6	week after the	5	0.62%
7	after the last	5	0.62%
8	the last dose	5	0.62%
9	of orserdu in	5	0.62%
10	human epidermal growth	5	0.62%
11	metastatic breast cancer	5	0.62%
12	for 1 week	5	0.62%
13	treatment with orserdu	5	0.62%
14	therapeutics inc a	5	0.62%
15	with orserdu and	5	0.62%
16	p et al	4	0.49%
17	avoid concomitant use	4	0.49%
18	concomitant use of	4	0.49%
19	neven p et	4	0.49%
20	during treatment with	4	0.49%
21	contraception during treatment	4	0.49%
22	stemline therapeutics inc	4	0.49%
23	who received orserdu	4	0.49%
24	females of reproductive	4	0.49%
25	epidermal growth factor	4	0.49%
26	of reproductive potential	4	0.49%
27	1 week after	4	0.49%
28	phase 3 trial	3	0.37%
29	of prior cdk46i	3	0.37%
30	growth factor receptor	3	0.37%

#	Keyword	Frequency	Density
1	of patients who received	6	0.71%
2	orserdu and for 1	5	0.59%
3	after the last dose	5	0.59%
4	and for 1 week	5	0.59%
5	with orserdu and for	5	0.59%
6	stemline therapeutics inc a	4	0.47%
7	human epidermal growth factor	4	0.47%
8	neven p et al	4	0.47%
9	during treatment with orserdu	4	0.47%
10	week after the last	4	0.47%
11	1 week after the	4	0.47%
12	treatment with orserdu and	4	0.47%
13	for 1 week after	4	0.47%
14	females of reproductive potential	4	0.47%
15	avoid concomitant use of	4	0.47%
16	patients who received orserdu	4	0.47%
17	use effective contraception during	3	0.35%
18	effective contraception during treatment	3	0.35%
19	use of strong or	3	0.35%
20	orserdu in patients with	3	0.35%
21	potential to use effective	3	0.35%
22	epidermal growth factor receptor	3	0.35%
23	concomitant use of strong	3	0.35%
24	orserdu were musculoskeletal pain	3	0.35%
25	contraception during treatment with	3	0.35%
26	strong or moderate cyp3a4	3	0.35%
27	duration of prior cdk46i	3	0.35%
28	cancer with disease progression	2	0.24%
29	factor receptor 2 her2negative	2	0.24%
30	or moderate cyp3a4 inducers	2	0.24%
31	orserdu avoid concomitant use	2	0.24%
32	receptor 2 her2negative esr1mutated	2	0.24%
33	with orserdu use in	2	0.24%
34	orserdu use in specific	2	0.24%
35	moderate cyp3a4 inhibitors with	2	0.24%
36	to use effective contraception	2	0.24%
37	populations lactation advise lactating	2	0.24%
38	with estrogen receptor erpositive	2	0.24%
39	breast cancer with disease	2	0.24%
40	17 of patients who	2	0.24%

#	URL	Whois	Check
1	https://www.orserdu.com	Whois	orserdu.com
2	https://stemline.com/privacy-policy/	Whois	stemline.com
3	https://stemline.com/ccpa-policy/	Whois	stemline.com
4	https://stemline.com/cookie-policy/	Whois	stemline.com
5	https://menarini.com	Whois	menarini.com
6	https://stemline.com	Whois	stemline.com